Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT05897541

PHASE3

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Sponsor: Shionogi

View on ClinicalTrials.gov

Summary

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.

Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

3701

Start Date

2023-06-09

Completion Date

2024-09-18

Last Updated

2026-10-07

Healthy Volunteers

Yes

Conditions

SARS-CoV-2 Infection

Interventions

DRUG

S-217622

Administered as a tablet.

DRUG

Placebo

Administered as a tablet.

Inclusion Criteria: Index Participants Only 1 index participant from each household will be enrolled in the study. Participants are eligible to be included as an index participant if all of the following criteria apply: 1. Pediatric participants or adult participants (of any age) 2. The index participant must: 1. Have at least 1 COVID-19 symptom within 24 hours before the index participant providing informed consent. COVID-19 symptom(s) must be deemed by the investigator as related to the current SARS-CoV-2 infection (not related to preexisting comorbidities) or deemed as preexisting and worsened due to SARS-CoV-2 infection. 2. Must have positive SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen from a sample collected prior to randomization of the participant 3. Must have a potential study participant who can participate in the study after onset of COVID-19 symptoms in an index participant Study Participants Multiple study participants from the same household are allowed to be enrolled in the study. The study intervention randomization will be performed based at the study participant's level. Participants will be eligible to be included in the study only if all of the following criteria apply: 1. ≥ 12 years of age at the time of signing the informed consent 2. Has a negative screening for SARS-CoV-2 infection, as determined by SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen (for example, oropharyngeal, nasopharyngeal or nasal swab, or saliva). 3. Has lived in household with index participant and will continue to live in same household and share common areas such as dining rooms and bathrooms until the end of the study 4. Must not be considered by the investigator or subinvestigator to have SARS-CoV-2 infection and: 1. No measured fever at Screening (defined as body temperature ≥ 38.0°Celsius \[C\] per tympanic or rectal thermometer or ≥ 37.5°C per axillary, oral, or forehead/temporal thermometer) 2. No COVID-19 symptoms at Screening (if a participant has COVID-19-like symptoms caused by comorbidities, only 1 symptom will be allowed) 5. Capable and willing to complete a participant diary 6. a. Male participants: Participants with partners that are woman of childbearing potential (WOCBP) must agree to use effective contraception. Participants with pregnant partners must agree to use effective contraception. b. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies: * Is not a WOCBP or * All of the following apply: * Is a WOCBP and using a contraceptive method that is effective as described in the protocol. * A WOCBP must have a negative urine pregnancy test within 24 hours before the first dose of study intervention period. * If a urine pregnancy test cannot be confirmed as negative (for example, an ambiguous result), a serum pregnancy test must be negative. * Additional requirements for pregnancy testing during and after study intervention as described in the protocol. * The investigator/subinvestigator will review medical history, menstrual history, and recent sexual activity to decrease the risk of inclusion of a woman with an early undetected pregnancy. 7. Participant must be randomized ≤ 72 hours from onset of COVID-19 symptoms in the index participant. Exclusion Criteria: Study Participants: Participants will be excluded from the study if any of the following criteria apply: 1. Tested positive for SARS-CoV-2 in the past 6 months. 2. Have an underlying disease requiring systemic corticosteroids (excluding topical), antipyretics/analgesics, or immunosuppressive agents. 3. Known current renal impairment defined as creatinine clearance \< 30 milliliters/minute by Cockcroft Gault or requiring dialysis. 4. Participants with severe liver dysfunction, such as known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy). 5. Received approved, authorized, or investigational convalescent plasma, or other anti- SARS-CoV-2 biologic products within 3 months of the Screening Visit 6. Received approved, authorized, or investigational anti-SARS-CoV-2 monoclonal antibodies (mAbs) in the last 6 months. 7. Received any SARS-CoV-2 vaccine within 6 months prior to the Screening Visit or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments until the end of the study. 8. Participants who have used any of the following drugs within 14 days prior to enrollment: 1. Strong cytochrome P450 (CYP) 3A inducer 2. Products containing St. John's wort 9. Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to the Screening Visit. 10. Positive urine pregnancy test at Screening Visit or are lactating. 11. Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo for S-217622. 12. Any condition or circumstance that, in the opinion of the investigator or subinvestigator, would compromise the safety of the participant or the quality of the study data. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Locations (178)

Central Alabama Research

Birmingham, Alabama, United States

Accel Research Site - Achieve - Birmingham - ERN - PPDS

Birmingham, Alabama, United States

Cullman Clinical Trials

Cullman, Alabama, United States

Absolute Clinical Research, LLC

Phoenix, Arizona, United States

One of a Kind Clinical Research Center LLC

Scottsdale, Arizona, United States

Healthstar Research

Hot Springs, Arkansas, United States

Preferred Research Partners - ClinEdge - PPDS

Little Rock, Arkansas, United States

Neighborhood Healthcare

Escondido, California, United States

Apex Research Group

Fair Oaks, California, United States

Ascada Research LLC

Fullerton, California, United States

Torrance Clinical Research Institute

Lomita, California, United States

Ark Clinical Research - Long Beach - ClinEdge - PPDS

Long Beach, California, United States

Rancho Cucamonga Clinical Research

Rancho Cucamonga, California, United States

Smart Cures Clinical Research

Rolling Hills Estates, California, United States

Clinical Trials Management Services, LLC

Thousand Oaks, California, United States

Lynn Institute of The Rockies - ERN - PPDS

Colorado Springs, Colorado, United States

TrueBlue Clinical Research

Brandon, Florida, United States

Invictus Clinical Research Group, LLC

Coconut Creek, Florida, United States

Universal Medical and Research Center, LLC

Coral Gables, Florida, United States

Hope Clinical Trials

Coral Gables, Florida, United States

I.V.A.M. Clinical & Investigational Center

Doral, Florida, United States

Quality Research of South Florida

Hialeah, Florida, United States

Universal Medical and Research Center, LLC Homestead

Homestead, Florida, United States

Flourish Research - Leesburg - PPDS

Leesburg, Florida, United States

Premier Clinical Research Institute - Miami - ClinEdge - PPDS

Miami, Florida, United States

LCC Medical Research - Miami - ClinEdge - PPDS

Miami, Florida, United States

CCM Clinical Research Group

Miami, Florida, United States

Suncoast Research Group LLC - Flourish - PPDS

Miami, Florida, United States

University of Miami - 1150 NW 14th St

Miami, Florida, United States

Florida Research Center, Inc.

Miami, Florida, United States

Oceane7 Medical & Research Center, Inc.

Miami, Florida, United States

Continental Clinical Research, LLC

Miami, Florida, United States

BioClinical Research Alliance

Miami, Florida, United States

Ivetmar Medical Group, LLC

Miami, Florida, United States

Miami Clinical Research - ClinEdge - PPDS

Miami, Florida, United States

Global Health Clinical Trials

Miami, Florida, United States

Valencia Medical and Research Center

Miami, Florida, United States

Alma Research

Miami, Florida, United States

GCP Global Clinical Professionals, LLC

Miami, Florida, United States

Research Institute of South Florida Inc

Miami, Florida, United States

Entrust Clinical Research

Miami, Florida, United States

Kendall South Medical Center

Miami, Florida, United States

Flourish Research - Miami - PPDS

Miami, Florida, United States

Meridian International Research

Miami Lakes, Florida, United States

MedQuest Translational Sciences

Miami Lakes, Florida, United States

Combined Research Orlando Phase I-IV LLC

Orlando, Florida, United States

Central Florida Internists - Conway

Orlando, Florida, United States

Accel Research Sites - Nona Pediatric Center - ERN - PPDS

Orlando, Florida, United States

Ormond Beach Clinical Research

Ormond Beach, Florida, United States

CTMD Research, Inc. Palm Springs - Hunt - PPDS

Palm Springs, Florida, United States

American Research Centers of Florida

Pembroke Pines, Florida, United States

Progressive Medical Research - ClinEdge - PPDS

Port Orange, Florida, United States

Renew Health Clinical Research, LLC

Tampa, Florida, United States

Bayside Clinical Research-West Tampa

Tampa, Florida, United States

Tampa Bay Health Care

Tampa, Florida, United States

Balanced Life Health Care Solutions - SKYCRNG - PPDS

Lawrenceville, Georgia, United States

Olivo Medical and Wellness Center

Chicago, Illinois, United States

Eagle Clinical Research

Chicago, Illinois, United States

KU Wichita Center for Clinical Research

Wichita, Kansas, United States

Voyage Medical - Michigan

Canton, Michigan, United States

Vida Clinical Sites

Dearborn Heights, Michigan, United States

Henry Ford Hospital

Detroit, Michigan, United States

Velocity Clinical Research - Covington - PPDS

Gulfport, Mississippi, United States

Montana Medical Research

Missoula, Montana, United States

Child Healthcare Associates - East Syracuse

East Syracuse, New York, United States

Rochester Clinical Research - ATLAS - Rochester - PPDS

Rochester, New York, United States

Lapis Clinical Research-Denver

Denver, North Carolina, United States

Progressive Medicine of the Triad, LLC

Winston-Salem, North Carolina, United States

WellNow Urgent Care & Research - Huber Heights

Dayton, Ohio, United States

PriMed Clinical Research - ClinEdge - PPDS

Dayton, Ohio, United States

Cyn3rgy Research - ClinEdge - PPDS

Gresham, Oregon, United States

Tristar Clinical Investigations, P.C.

Philadelphia, Pennsylvania, United States

Frontier Clinical Research - Scottdale

Scottdale, Pennsylvania, United States

Coastal Pediatric Associates

Charleston, South Carolina, United States

SPICA Clinical Research

Columbia, South Carolina, United States

Main Street Physicians Care - Waterway

Little River, South Carolina, United States

Clinical Trials of South Carolina - ClinEdge - PPDS

Moncks Corner, South Carolina, United States

Saint Hope Foundation Inc

Bellaire, Texas, United States

ACRC Trials - Carrollton - Hunt - PPDS

Carrollton, Texas, United States

Global Medical Research - M3 WR

Dallas, Texas, United States

Alina Clinical Trials, LLC

Dallas, Texas, United States

Southwest Family Medicine Associates

Dallas, Texas, United States

Epic Medical Research LLC - DeSoto

DeSoto, Texas, United States

Care United Research, LLC - Elligo - PPDS

Forney, Texas, United States

Valley Institute of Research

Fort Worth, Texas, United States

C & R Research Services USA

Houston, Texas, United States

New Horizon Medical Group, LLC

Houston, Texas, United States

Care and Cure Clinic

Houston, Texas, United States

DCT-McAllen Primary Care Research, LLC dba Discove

McAllen, Texas, United States

Advances In Health Inc

Pearland, Texas, United States

Clinical Associates in Research Therapeutics of America

San Antonio, Texas, United States

VIP Trials

San Antonio, Texas, United States

Tranquil Clinical Research

Webster, Texas, United States

Alliance for Multispecialty Research, LLC - Kaysville - PPDS

Kaysville, Utah, United States

Alliance for Multispecialty Research LLC - Roy

Roy, Utah, United States

Hospital Interzonal General de Agudos Vicente Lopez Y Planes

General Rodriguez, Buenos Aires, Argentina

Clínica Privada Independencia

Munro, Buenos Aires, Argentina

Centro Médico San Nicolás Grupo Oroño

San Nicolás de los Arroyos, Buenos Aires, Argentina

Instituto de Investigaciones Clínicas Zárate

Zárate, Buenos Aires, Argentina

Instituto Médico Río Cuarto

Río Cuarto, Córdoba Province, Argentina

And 78 more locations on ClinicalTrials.gov

Clinical Research Directory

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (178)